Acidan (Mefenamic Acid) is commonly used to help with symptomatic relief of mild to moderate pain, and is applied in addressing symptoms related to inflammation and fever. The medication is generally applied in contexts where short-term symptomatic assistance is needed.

---

This substance is relevant for easing symptoms that become disruptive during episodes of sudden escalation, particularly in conditions involving inflammatory or irritative states. It is commonly used for managing painful menstrual symptoms and those related to menorrhagia (primary dysmenorrhea), as well as acute discomfort following dental procedures, musculoskeletal injuries, and the stiffness associated with chronic joint conditions like arthritis.

Acidan is applied across therapeutic domains where additional symptomatic support is needed. It assists with maintaining functional stability, offering supportive relief when symptoms interfere with routine activities, and is relevant for managing elevated body temperature (fever).

---

Summary of Therapeutic Focus
Primary Focus	Symptomatic relief of primary dysmenorrhea (menstrual cramps) and mild to moderate acute pain.
Symptom Profile	Applied in situations where pain, inflammation, and fever occur together.
Patient Benefit	Contributes to improved day-to-day comfort during symptomatic periods and assists with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus Drug Information

Acidan (Mefenamic Acid) use is strictly governed by population eligibility rules defined in official regulatory labeling. Use is contraindicated in several specific patient groups to prevent serious complications.

---

Absolute Contraindications

The medicine must not be used by individuals with a known hypersensitivity to mefenamic acid or any other Nonsteroidal Anti-Inflammatory Drug (NSAID), including those who have experienced allergic symptoms such as asthma or hives after taking these drugs. It is also strictly contraindicated for patients diagnosed with severe heart failure, severe hepatic failure, or significantly impaired renal function.

Patients with active ulceration or chronic inflammation of the upper or lower gastrointestinal tract, or a history of recurrent peptic ulcer/hemorrhage, are also ineligible. Use is prohibited in the setting of peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery.

---

Specific Population Restrictions

Age: The drug is typically approved for use in Adults and certain Adolescents (e.g., age 14 and older). Safety and effectiveness are not established for all younger pediatric age groups. Geriatric patients must use the medicine with particular caution due to an increased risk of serious adverse events.

Pregnancy and Lactation: Acidan is contraindicated during the third trimester of pregnancy (at or after 20 weeks’ gestation) and is not recommended for use by nursing mothers.

Conditional Use: Caution is required for patients with uncontrolled hypertension or established cardiovascular disease. Individuals with dehydration must have this condition corrected before starting therapy.

Acidan Interactions with other medicines and products

Acidan (Mefenamic Acid) has specific interaction patterns documented in official regulatory labeling that necessitate caution or prohibition with certain medicines and substances.

---

Contraindicated and Avoided Combinations

The medicine is strictly contraindicated for treating peri-operative pain associated with Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other systemic non-aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, should be avoided due to an additive risk of serious gastrointestinal events.

---

Interactions Increasing Bleeding and Reducing Efficacy

A significant pharmacodynamic interaction involves Oral Anticoagulants (such as Warfarin), where co-administration enhances the risk of both gastrointestinal and non-gastrointestinal bleeding. It also interferes with the anti-platelet effect of low-dose Aspirin. Furthermore, Acidan can reduce the efficacy of various Anti-hypertensive Agents and Diuretics through prostaglandin synthesis inhibition.

---

Interactions Affecting Drug Exposure

Acidan is documented to alter the levels of specific co-administered drugs. It reduces the renal clearance of Lithium and Methotrexate, leading to increased plasma concentrations of these medicines. Concomitant use with antacids containing Magnesium Hydroxide is documented to significantly increase the rate and extent of Acidan's own absorption. The drug is primarily metabolized via the CYP2C9 enzyme.

---

Other Substance and Population Notes

The ingestion of Alcohol carries an increased additive risk of stomach bleeding. In patients with impaired renal function or the elderly, the co-administration with ACE inhibitors, ARBs, and/or diuretics carries a heightened risk of renal function deterioration.

How Acidan Works: Molecular Mechanism of Action

Acidan (Mefenamic Acid) operates via a dual mechanism centered on enzyme inhibition and ion channel modulation, influencing biological pathways that modulate prostanoid synthesis and cellular excitability. This primary domain involves the rapid, non-selective, and reversible inhibition of both Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. By blocking the COX enzymes, Acidan suppresses the conversion of Arachidonic Acid into prostaglandins ( PGE2 and PGF2alpha) and other prostanoids. This molecular interference modifies early steps in the Arachidonic Acid cascade, thereby decreasing PGE2 synthesis. This consequence reduces the degree of sensitization in peripheral nociceptive neurons and permits a downward adjustment of the hypothalamic thermoregulatory set-point.

This secondary domain engages mechanisms independent of prostaglandin suppression, specifically involving the direct modulation of certain potassium ion (mathbfK^+) channels found on smooth muscle cell membranes. By activating these mathbfK^+-channels, the drug promotes cellular hyperpolarization, which alters the excitability and contractile activity of the muscle tissue. Additionally, as a fenamate, Acidan may influence biological processes by potentially affecting other inflammatory complexes, such as the NLRP3 inflammasome, further altering signal transduction pathways.

Acidan (Mefenamic Acid) is available for oral administration in specific formulations, including capsules, tablets, and oral suspensions. Official usage follows a defined, short-term protocol that strictly dictates the amount, frequency, and duration of intake.

The general principle of use is to utilize the lowest effective dose for the shortest duration necessary.

Labeled Dosing and Administration

Feature	Official Guideline
Route of Administration	Oral (by mouth).
Standard Adult Dosing	Begins with an initial 500 mg dose, followed by a maintenance dose of 250 mg.
Dosing Frequency	The maintenance dose is typically taken every six hours (q6hr) as needed.
Administration Condition	Must be taken with food, milk, or a full glass of water to ensure proper intake.

For indications such as primary dysmenorrhea, administration should begin at the onset of bleeding and associated symptoms. The course is strictly time-limited, generally not exceeding 2 to 3 days for primary dysmenorrhea and not exceeding 7 days for acute pain.

The official regimen for acute pain and primary dysmenorrhea is typically applied to patients 14 years and older. Older adults follow the lowest effective dosing for the shortest duration due to age-related considerations. If a dose is missed, the protocol is to skip the missed dose and take the next dose at the regularly scheduled time; doses should not be doubled.

Research Evidence / Overview of Studies for Acidan

---

Evidence for Use in Primary Dysmenorrhea (Menstrual Pain)

Research exploring how symptoms change over time in women experiencing menstrual pain has been primarily structured around short-term Randomized Controlled Trials (RCTs). These studies included adolescent and adult women and examined outcomes related to physical discomfort, focusing on how patients reported changes in pain intensity scores and how studies monitored the use of supplemental pain relief. Findings from systematic reviews describe that the studies reported measurements of change in patient-reported outcomes describing perceived discomfort. However, the existing research primarily addresses acute symptom changes only during the short study period, and long-term effects over many years are not fully established by current RCTs.

---

Evidence for Use in Acute Mild to Moderate Pain

Mefenamic Acid was studied in research contexts exploring acute pain, such as pain experienced after dental procedures. Research is mainly structured around very short-term, single-dose RCTs in adult populations. The research examined outcomes centered on patient-reported outcomes describing perceived discomfort over a period of just a few hours. In these research scenarios, trials described patterns such as a calculated difference in pain outcome measurements versus controls. Despite these findings, the overall sample sizes were modest in some pooled data analyses for acute pain endpoints, and the evidence base provides limited insight into multi-day study durations for general acute pain.

---

Key Evidence Gaps and Areas of Uncertainty

Scientific literature and regulatory assessments identify several areas where more research is needed or where certainty remains low. A recurring theme across the research is that follow-up durations were limited, resulting in limited information for long-term outcomes regarding patient experience beyond short-term symptomatic relief. While the evidence base for menstrual pain has a well-established structure, the evidence quality varies across studies depending on the specific research scenario and population examined. Furthermore, comparative evidence is limited against all major active control treatments in some acute pain settings.

Key Studies & References

1. Mefenamic acid and diclofenac in the treatment of menorrhagia and dysmenorrhea in dysfunctional uterine bleeding: a randomized comparative study
2. Mefenamic Acid 500 mg film-coated Tablets Public Assessment Report (Regulatory Summary)

Common questions about Acidan (FAQ)

Q: How quickly can I expect Acidan to start working?

A: Official information indicates that Acidan is absorbed quickly after it is taken. Peak concentrations of the active ingredient are typically observed in the bloodstream between one to four hours after a dose. The time to initial onset of symptomatic relief has been reported in studies as generally within 30 minutes or more.

Q: What is the typical timeframe for seeing the full effect of Acidan?

A: Acidan has a relatively short half-life, meaning the medicine is processed and eliminated from the body within a few hours. The documented dosing frequency (e.g., every six hours) aligns with the drug's short half-life and is intended to maintain appropriate concentrations for symptom management.

Q: Do older adults react differently to Acidan compared to younger people?

A: Official warnings note that older adults, or geriatric patients, have an increased risk for more severe gastrointestinal adverse events, including those that can be serious. Because of this heightened risk, official prescribing information emphasizes using the lowest effective amount for the shortest time necessary to control symptoms.

Q: Why do official sources list so many potential side effects for Acidan?

A: Drug labels are required by regulatory agencies to consolidate and list every adverse event that was reported during clinical trials or through post-market surveillance. This thorough listing reflects the regulatory requirement for transparent documentation of the range of reported experiences.

Q: Can Acidan be used safely by women who may become pregnant?

A: Official labeling advises that Acidan should be used cautiously by women who are planning to become pregnant. The medication can inhibit the production of prostaglandins, which are body chemicals that are noted to potentially interfere with or prolong pregnancy. Official labeling states that women who are of childbearing potential or who plan to become pregnant should have a discussion regarding the use of this medicine with a healthcare professional.

Q: Is it possible to have an allergic reaction to Acidan?

A: Yes, regulatory documents list hypersensitivity as an absolute contraindication for use. This means the medicine must not be used by individuals who have a known allergy to mefenamic acid or any other Nonsteroidal Anti-Inflammatory Drug (NSAID). Serious allergic reactions have been reported across the NSAID class.

Q: How does the official documentation describe the 'mechanism of action' for Acidan?

A: Official documentation describes the way Acidan works as having analgesic (pain-relieving), anti-inflammatory, and fever-reducing properties. The core molecular process involves the drug inhibiting the synthesis of prostaglandins, which are natural substances in the body that initiate signals for pain and inflammation.

Q: Is Acidan the same kind of medicine as other drugs that treat similar conditions?

A: Acidan contains Mefenamic Acid, which is formally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). While it belongs to the same broad category as many other common pain and fever medicines, it is specifically classified as a fenamate, distinguishing it from other types of NSAIDs.

Q: Why is Acidan prescribed for this specific condition?

A: The official uses (labeled indications) for Acidan include the short-term relief of mild to moderate pain from various causes, as well as the treatment of primary dysmenorrhea (menstrual cramps). The medicine's anti-inflammatory and pain-relieving properties are considered suitable for these specific, time-limited conditions.

Q: Are there specific foods or drinks to avoid while using Acidan?

A: Official drug labels state that taking the medicine with alcohol may increase the risk of gastrointestinal bleeding. There is no official warning listed against most other specific foods or drinks.

Q: Can Acidan affect the results of common lab tests?

A: Official documentation notes that Acidan may cause false-positive reactions for the presence of bile in the urine when certain types of laboratory tests are used. Official documentation has also reported borderline or temporary elevations in one or more liver function tests.

Q: Is there a maximum amount of time someone can safely use Acidan?

A: Yes, official labeling specifies strict time limits for the use of Acidan to minimize potential serious risks. For acute pain, treatment should generally not last longer than seven days, and for primary dysmenorrhea, treatment should typically not exceed two or three days.

Q: Does Acidan affect a person's ability to drive or operate machinery?

A: Official safety information reports that some individuals may experience adverse effects such as dizziness, drowsiness, or visual disturbances. Official documentation suggests that individuals who experience these effects should exercise caution and avoid driving or operating machinery until they are certain the medicine does not impair their function.

Q: Can the use of Acidan affect a person's mental state?

A: Official documentation lists effects on the central nervous system (CNS) such as headache and dizziness as possible adverse reactions. Although not common, there have been rare reports of more severe central nervous system effects, such as aseptic meningitis, primarily in patients with certain underlying conditions.

Q: Are there different forms or strengths of Acidan available?

A: Yes, the drug is officially available in a few different forms, including capsules and an oral suspension (liquid). The most common capsule strength is 250 mg, which is often used in combination to achieve the full initial and maintenance amounts.

Q: How is Acidan classified by major health agencies?

A: Major health agencies officially classify Acidan (Mefenamic Acid) as a Nonsteroidal Anti-Inflammatory Drug (NSAID). In most regions, official regulatory guidelines also categorize it as a Prescription-Only Medicine (POM).

Q: Does the effectiveness of Acidan change over time?

A: Official prescribing information generally focuses on the medicine's short-term efficacy, aligning with its time-limited use (e.g., 7 days or less). Regulatory documents do not extensively discuss whether the body develops tolerance or if effectiveness changes over long periods.

Q: What is the difference between the main use of Acidan and its possible other uses?

A: The main uses of Acidan are those officially defined and approved by regulatory agencies, such as the treatment of primary dysmenorrhea and mild-to-moderate pain. Any other reported use is not addressed in the official prescribing information, which focuses only on the approved indications.

Q: Can Acidan be taken on an empty stomach?

A: Official administration instructions specify that Acidan must be taken with food, milk, or a full glass of water. This guidance is typically provided because taking the drug with food or liquid may help minimize the risk of gastrointestinal side effects, which are commonly associated with NSAIDs.

Q: What distinguishes Acidan from non-drug treatments for the same condition?

A: The primary distinction documented in regulatory sources is that Acidan is a medicine that works by directly interfering with the body's chemistry. It operates by inhibiting the biological synthesis of prostaglandins, which are natural substances in the body that initiate signals for pain and inflammation. Non-drug treatments do not share this molecular action.

Q: How does Acidan compare to generic versions of similar drugs?

A: Generic versions of brand-name medicines like Acidan are required by regulatory agencies to demonstrate bioequivalence. This requires that the generic product demonstrate it delivers the same amount of the active ingredient to the bloodstream within a comparable timeframe as the brand-name product.

Q: Are there long-term studies available on Acidan's effects?

A: Reviews of the available research evidence indicate that most clinical trials for Acidan had limited follow-up periods. Consequently, the official evidence base provides limited information regarding the long-term outcomes of patient experience beyond short-term symptomatic relief.

Q: Does Acidan affect sleep patterns?

A: Official safety information reports drowsiness and fatigue as possible adverse effects on the nervous system. While these reports do not specifically name sleep disturbances, these kinds of effects could potentially be linked to changes in a person's sleep-wake cycle.

Official Storage and Handling Requirements

Acidan (mefenamic acid) must be stored at room temperature, generally between 20 C and 25 C (68 F and 77 F), and must not be stored above 30 C (86 F). The medication must be protected from light, moisture, and excess heat, and must be kept from freezing.

Always store the medication in its original container, ensuring the lid is tightly closed to maintain product stability. Per regulatory requirements, keep all medicine out of the reach of children and pets.

Disposal of Unused Medication

Expired or unused Acidan should be disposed of properly. The preferred method is to utilize a community drug take-back program or mail-back service. If these are unavailable, the medication should be mixed with an undesirable substance (such as used coffee grounds or dirt) and placed in a sealed container before being thrown into the household trash. The product should not be released into the environment, such as down drains or into wastewater.